doi: 10.2337/dc19-0749 Summary Keywords obesity, oral semaglutide, GLP-1 receptor agonist, efficacy, safety, real-world evidence, weight loss Citation Krajnc M, Kuhar N and Koceva A (2025) Oral semaglutide for the treatment of obesity: a retrospective real-world study
That brings us to: Building a GLP-1 portfolio Core drug developers | 88% Unsurprisingly, the majority of our investment must be allocated to the core drug developers
While NYHA classification was not available in our dataset, the post-propensity matched mean ejection fraction of 39 % suggests a population that may be less severely affected than those included in the FIGHT or LIVE trials
Jin S et al
The forensic data confirms a fundamental shift: Forensic Insight: The industry is effectively replacing a transactional sales model (take a pill, get cured) with a lifelong annuity model (take a shot forever)